Core Viewpoint - HBN has established itself as a leading domestic skincare brand in China, particularly known for its effective retinol products and the "early C, late A" skincare philosophy, and is now seeking to go public on the Hong Kong Stock Exchange [1][3]. Group 1: Brand Development and Market Position - HBN was founded in 2019 and chose to focus on the challenging retinol market, which was dominated by international brands, by emphasizing ingredient transparency and authoritative evidence [3][4]. - The brand has successfully positioned itself in the market by introducing a comprehensive product line that includes retinol-based skincare products, achieving the highest sales in its category from 2022 to 2024 [4][6]. Group 2: Research and Development Strategy - HBN has invested heavily in R&D and established a comprehensive verification system to ensure that all product claims are backed by clinical data, making it the only Chinese skincare brand to conduct efficacy testing through international authorities [6][7]. - The company has developed a sustainable innovation system that allows for the efficient reuse of research outcomes, leading to the continuous launch of new products and categories [7][9]. Group 3: Financial Performance and User Engagement - As of September 2025, HBN has accumulated over 4.6 million repeat customers, with average repurchase rates of approximately 35.4% on Tmall and 44.0% on Douyin, significantly higher than industry averages [10]. - Financially, HBN reported total revenue of 2.083 billion yuan in 2024, with net profit rising to 129 million yuan, and a 190.3% year-on-year increase in net profit for the first three quarters of 2025 [10].

Core Viewpoint - The IPO application of HBN, a domestic skincare brand, signifies a shift in the beauty industry towards a focus on sustainable product innovation and core technological barriers, moving away from mere GMV growth and marketing volume [7] Group 1: Company Overview - HBN's parent company, Shenzhen Hujia Technology (Group) Co., Ltd., has submitted an IPO application to the Hong Kong Stock Exchange, aiming to be the "first stock of true efficacy skincare" [1] - The company has established a rigorous efficacy verification system and is the only skincare brand in China to conduct real-person efficacy testing on all its products through an international authority [5] Group 2: Financial Performance - HBN's revenue is projected to grow from 1.948 billion yuan in 2023 to 2.083 billion yuan in 2024, with a 10.2% increase in the first three quarters of 2025, reaching 1.514 billion yuan [3] - The net profit is expected to rise significantly from 39 million yuan in 2023 to 129 million yuan in 2024, and has already reached 145 million yuan in the first three quarters of 2025, with the net profit margin increasing from approximately 2% to nearly 10% [3] Group 3: User Engagement - HBN has accumulated over 4.6 million repeat customers, with average repurchase rates of 35.4% on Tmall and 44.0% on Douyin, significantly higher than the industry average of 20% [3] - The success of HBN's high repurchase rates is attributed to its strong product matrix, including top-selling items like the α-arbutin essence and caffeine eye cream, which have consistently ranked first in their categories [3] Group 4: Research and Development - HBN has made substantial investments in R&D, with a focus on building a comprehensive research chain covering basic research, raw material innovation, and efficacy validation [4] - The company has published 50 SCI papers, ranking first among domestic skincare brands, and has successfully registered four new self-developed cosmetic raw materials, placing third in the domestic skincare brand category [4] Group 5: Market Trends - The market is shifting towards "scientific-driven growth," with a focus on effective skincare products that address specific skin issues, indicating a move away from generalized marketing concepts [7] - HBN's approach demonstrates that long-term investment in research can build "hard power" and drive high-quality growth and user trust, providing a viable path for domestic beauty brands to compete and move upscale [7]

Core Viewpoint - HBN, a skincare brand, has submitted its application for a mainboard listing on the Hong Kong Stock Exchange, aiming to become the first stock representing "true efficacy skincare" in China and to leverage international capital markets for long-term development [1] Group 1: Company Overview - HBN was founded in 2019 with a commitment to the philosophy of "true efficacy" and a belief in the long-termism of "slow research" [2] - The brand has established itself among the top ten domestic skincare brands in China and is the largest domestic brand in the improvement skincare market [2] - HBN is recognized as a pioneer in the domestic retinol anti-aging sector and was one of the first brands to propose the "morning C, evening A" skincare concept [2] Group 2: Market Position and Performance - HBN's retinol and α-arbutin products have ranked first in sales in their categories for three consecutive years (2022-2024), creating a rare series of enduring bestsellers among domestic brands [2] - The company has accumulated over 4.6 million repeat customers, with average order values steadily increasing [3] - HBN's average repurchase rates on platforms like Tmall and Douyin are 35.4% and 44.0% respectively, significantly exceeding industry averages [3] Group 3: Financial Performance - HBN has experienced steady revenue growth, with total revenue reaching 2.08 billion yuan in 2024 and 1.51 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 10.2% [4] - Adjusted net profit increased from 90 million yuan in 2023 to 130 million yuan in 2024, and further to 150 million yuan in the first three quarters of 2025 [4] - The adjusted net profit margin improved from 4.7% in 2023 to 6.2% in 2024, and reached 9.6% in the first three quarters of 2025, indicating a transition to a sustainable growth phase [4] Group 4: Research and Development - HBN has published 50 SCI-indexed papers, ranking first among domestic skincare brands for papers published as the first author [3] - The company ranks third among domestic brands in the number of new cosmetic raw materials registered by its own research and development as of September 2025 [3] - HBN has established a rigorous efficacy verification system and is the only skincare brand in China to conduct real-world efficacy testing for its entire product line through an international authority [3] Group 5: Future Outlook - HBN aims to establish a comprehensive multi-dimensional efficacy verification system throughout the product lifecycle, expanding verification from laboratories to real-world settings [4] - The company is promoting the establishment of industry standards for cosmetic efficacy evidence assessment, which is expected to lead to more standardized and transparent efficacy claims across the industry [4] - The upcoming listing in Hong Kong is seen as a critical step for HBN to transform its systematic research capabilities into broader market influence [5]

Core Viewpoint - Shenzhen HBN Technology (Group) Co., Ltd. is set to list on the Hong Kong Stock Exchange, aiming to become the first stock representing "true efficacy skincare" in China, showcasing a model of sustainable growth driven by systematic innovation in research and development [2][12]. Group 1: Company Overview - Founded in 2019, HBN adheres to the philosophy of "true efficacy" and believes in a long-term approach to research, focusing on building a healthy and sustainable brand development path [4]. - HBN has established itself among the top ten domestic skincare brands in China and is the largest domestic brand in the improvement skincare market, according to a report by ZhiShi Consulting [5]. Group 2: Market Position and Product Leadership - HBN has achieved a leading market position, particularly in the A-retinol anti-aging category, being one of the first domestic brands to propose the "morning C, evening A" skincare concept. Its A-retinol products have ranked first in sales for three consecutive years from 2022 to 2024 [7]. - The company has published 50 papers in SCI-indexed journals, ranking first among domestic skincare brands for first-author publications, demonstrating its strong research capabilities [8]. Group 3: User Trust and Financial Performance - HBN has accumulated over 4.6 million repeat customers, with average transaction values steadily increasing. The brand's average repurchase rates on platforms like Tmall and Douyin reached approximately 35.4% and 44.0% in 2025, significantly exceeding industry averages [10]. - The company reported a total revenue of 2.08 billion yuan in 2024, with a year-on-year growth of 10.2% in the first three quarters of 2025, and adjusted net profits increased from 90 million yuan in 2023 to 150 million yuan in the first three quarters of 2025 [10]. Group 4: Industry Growth and Future Potential - The skincare market in China is experiencing structural growth, with the top ten dermatological skincare brands projected to exceed 30 billion yuan in retail sales by 2024, reflecting a compound annual growth rate of over 16.7% from 2019 to 2024, outpacing the overall industry growth rate of approximately 8.6% [13]. - HBN is establishing a comprehensive efficacy verification system that spans the entire product lifecycle, aiming to enhance the credibility of efficacy claims and promote a more standardized approach within the industry [13][14].